ABSTRACT
INTRODUCTION
HIV protease and reverse transcriptase (RT) are two major drug targets in HIV therapy with several drugs developed to inhibit their functions. However, the HIV virus is capable to escape current antiviral therapy directed at these targets by evolving into drugresistant variants with highly complex mutation patterns. Drugs show different efficiency for different viral strains, and it is important to pick the medication which most efficiently can block HIV on individual patient basis. Several attempts have been made to produce models to predict drug susceptibility based on the sequenced HIV (Beerenwinkel et al., 2003; Liu and Shafer, 2006 ), but the current models are commonly trained only on data for one drug and hence do not make full use of the available information. Expert systems are also present (Liu and Shafer, 2006) , which build on the experience of physicians and are hence unable to extrapolate and predict the effect of novel mutations. The services presented here are founded on proteochemometric models for HIV proteases and reverse transcriptases, a technology which typically produces accurate predictions based on more information (Kontijevskis et al., 2008) . * To whom correspondence should be addressed. 
METHODS

HIV protease drug susceptibility prediction
The proteochemometric model described in Lapins et al. (2008) allows for prediction of drug susceptibility of seven clinically used protease inhibitors (PIs) from the HIV protease sequence. The model is based on 828 mutated HIV protease genome sequences and the experimental susceptibility data for the seven protease inhibitors measured by their ability to inhibit the replications of the respective mutated HIV variant in vitro; in total the model is based on 4794 protease sequence-inhibitor combinations.
HIV-RT drug susceptibility prediction
The proteochemometric model described in Junaid et al. (2010) allows for prediction of drug susceptibility of eight clinically used nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs). The model is based on 728 mutated HIV RT genome sequences and the experimental susceptibility data for the eight NRTIs measured by their ability to inhibit the replications of the respective mutated HIV variant in vitro; in total the model is based on 4495 RT sequence-inhibitor combinations.
Model validation
Both proteochemometric models were thoroughly statistically validated, among several methods using cross-validation and external predictions for new virus isolates. The protease model was validated by double loop crossvalidation, with inner Q 2 = 0.87 and outer Q 2 = 0.85. RT model was validated by CV (Q 2 = 0.89) and by external test set comprizing 30% of HIV isolates (Q 2 = 0.86). Q 2 is an estimate of a model's predicitve performance and ranges from −∞ to 1, where 1 indicates perfect prediction (see Equation 3 in Freyhult et al. (2005) for details on the Q 2 statistic). We also performed permutation tests to ensure that the models were not overfitted. See Lapins et al. (2008) and Junaid et al. (2010) for more details on model validation. 
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IMPLEMENTATION
The two services were implemented as Web services, available from the server ws1.bmc.uu.se. The services accept a mutated PI or NRTI sequence as input (in plain text or FASTA format), and outputs the predicted susceptibility values. The HIV protease drug susceptibility prediction service, and the HIV-RT drug susceptibility prediction service were implemented as XMPP services (Wagener et al., 2009) . A REST interface was also added to both services, to provide an additional way to invoke them. Implementation details are available from the web page http://www.hivdrc.org/webservices. Both REST services are registered in BioCatalogue (Bhagat et al., 2010) . Web pages were established to allow for entering sequences with one or many mutations, and submit for prediction of susceptibility by the two Web services with results visualized in a chart (see Fig. 1 ). A summarizing feature comparison between servers for susceptibility prediction are available in Table 1 . Notably, only the HIV Drug Research Centre (HIVDRC) services are available as REST and XMPP services, making them the most interoperable services available for HIV susceptibility prediction. EuResist (Zazzi et al., 2011) was not included in the list as it does not predict virus susceptibility to individual drugs but the probability of success of common treatment regimens (combinations of 2-4 drugs) after 8 weeks of treatment.
A set of plugins were also constructed to integrate the HIVDRC services into the graphical platform Bioclipse (Spjuth et al., 2007) . The services can be accessed both from the graphical user interface and from scripts (Spjuth et al., 2009) .
CONCLUSION
We here present two Web services that predict drug susceptibility for PIs and NRTIs from the mutation patterns of different HIV strains' genome sequences. The services are based on a comprehensive analysis of HIV protease and RT inhibitors, using data from all drugs in each model, resulting in a proteochemometric model with excellent predictive ability. The implementation as Web services allows for programmatic access to the services, and for inclusion in workflows.
The binding sites for NNRTIs and NRTIs are different so these compounds cannot be incorporated into one proteochemometric model. A separate proteochemometric model for predictions of NNRTI drugs is in development.
